Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc (PRGO), a global pharmaceutical company incorporated in Ireland, filed this Current Report on August 6, 2025. The filing announces the release of earnings for the second quarter ended June 28, 2025. The report serves to disclose the availability of the earnings press release (Exhibit 99.1) and outlines the company's methodology for non-GAAP financial measures.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the attached press release (Exhibit 99.1) as the source for these figures. The document details the adjustments used to calculate non-GAAP measures, including adjusted net income, adjusted operating income, free cash flow, and constant currency net sales.
Material Changes and Adjustments
The filing lists specific items excluded from non-GAAP calculations to facilitate period-to-period comparability. For the three months ended June 28, 2025, adjustments included amortization expense, unusual litigation, restructuring charges, loss on divestitures, impairment charges, and foreign currency translation movements. Comparisons to the prior year period (ended June 29, 2024) note additional adjustments for infant formula remediation and acquisition-related charges in the prior year.
Guidance, Outlook, and Management Commentary
Management utilizes non-GAAP measures for planning, forecasting, and evaluating segment performance. The filing emphasizes that these measures exclude items such as amortization of acquired intangible assets, which are not affected by current period operations, to better reflect underlying business trends. No specific forward-looking guidance or quantitative outlook is provided within this 8-K text; investors are directed to the attached press release for detailed commentary.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2025 revenue, earnings per share, and cash flow figures.
- Verify the magnitude of "unusual litigation" and "infant formula remediation" costs impacting GAAP results.
- Confirm the reconciliation between GAAP and non-GAAP net income and operating margins.
- Assess the impact of foreign currency translation on reported sales growth.
- Check for any updates on restructuring charges or impairment charges mentioned in the adjustments list.